John Wiley & Sons Pharmaceutical Amorphous Solid Dispersions Cover Providing a roadmap from early to late stages of drug development, this book overviews amorphous sol.. Product #: 978-1-118-45520-3 Regular price: $170.09 $170.09 Auf Lager

Pharmaceutical Amorphous Solid Dispersions

Newman, Ann (Herausgeber)

Cover

1. Auflage April 2015
504 Seiten, Hardcover
Wiley & Sons Ltd

ISBN: 978-1-118-45520-3
John Wiley & Sons

Kurzbeschreibung

Providing a roadmap from early to late stages of drug development, this book overviews amorphous solid dispersion technology - a leading platform to deliver poorly water soluble drugs, a major hurdle in today's pharmaceutical industry. Chapters, written by contributing authors on the frontlines of R & D, cover topics that include: physical and chemical properties, screening, scale-up, formulation, drug product manufacture, intellectual property, and regulatory considerations.

Weitere Versionen

epubpdf

Providing a roadmap from early to late stages of drug development, this book overviews amorphous solid dispersion technology - a leading platform to deliver poorly water soluble drugs, a major hurdle in today's pharmaceutical industry.
* Helps readers understand amorphous solid dispersions and apply techniques to particular pharmaceutical systems
* Covers physical and chemical properties, screening, scale-up, formulation, drug product manufacture, intellectual property, and regulatory considerations
* Has an appendix with structure and property information for polymers commonly used in drug development and with marketed drugs developed using the amorphous sold dispersion approach
* Addresses global regulatory issues including USA regulations, ICH guidelines, and patent concerns around the world

Contents

Contributors

Preface

Chapter 1: Introduction to Amorphous Solid Dispersions
George Zografi and Ann Newman

Chapter 2: Polymers and Surfactants
Padma Narayan, William W. Porter III, Meinolf Brackhagen, and Christopher Tucker

Chapter 3: Amorphous Solid Dispersion Screening
Ann Newman

Chapter 4: Solid state Characterization of Amorphous Dispersions
Frederick G. Vogt

Chapter 5: Physical Stability and Crystallization Inhibition
Lynne S. Taylor

Chapter 6: Solubility and Dissolution Considerations for Amorphous Solid Dispersions
Grace A. Ilevbare, Wei Xu, Christopher T. John, James Ormes, Jesse Kuiper, Allen C. Templeton, and Annette Bak

Chapter 7: Translational Development of Amorphous Dispersions
Patrick Connelly, Brian Patrick Quinn, Steve Johnston, Philip Bransford, Praveen Mudunuri, Andrey Peresypkin, Majed Fawaz, Setu Roday, Anuj Kuldipkumar, Hong-Ren Wang, Phillip Snyder, Jeff Katstra, Tapan Sanghvi, Bill Rowe, and Patricia Hurter

Chapter 8: Preclinical and Clinical Studies
Marcus E. Brewster, Geert Verreck, Jan Bevernage, Joachim Brouwers, Guy Van den Mooter, and Patrick Augustijns

Chapter 9: Spray-Drying and Scale-Up
Daniel E. Dobry, Dana M. Settell, and John M. Baumann

Chapter 10: Hot Melt Extrusion of Amorphous Solid Dispersions
Kieran Crowley and Andreas Gryczke

Chapter 11: Formulation Development of Amorphous Dispersions
Tapan Sanghvi, Jeff Katstra, Brian Patrick Quinn, Hayden Thomas, and Patricia Hurter

Chapter 12: Scientific and Regulatory Considerations in Product Development
Abhay Gupta, Ziyaur Rahmna, and Manssor A. Khan

Chapter 13: Chapter Patenting Amorphous Solid Dispersions of Pharmaceuticals
Jeffry A. Lindeman

Chapter 14: Monographs on Polymers and Surfactants
Xia Lu, Robert Wenslow, and Ann Newman

Appendix 1
Xia Lu, Robert Wenslow, and Ann Newman

Appendix 2: Marketed Products
Ann Newman
Ann Newman is a pharmaceutical consultant with Seventh Street Development Group, where she provides consulting, training, and webcast services on solid-state pharmaceutics and pharmaceutical development. She is also an Adjunct Professor and Lecturer in the Department of Industrial and Physical Pharmacy at Purdue University. A senior pharmaceutical scientist with demonstrated scientific and leadership expertise in the pharmaceutical industry, Dr. Newman has over 25 years of large pharma and contract research experience.